NATCO Pharma Limited (NSE: NATCOPHARM)
India
· Delayed Price · Currency is INR | Market Cap | 243.16B |
| Revenue (ttm) | 45.64B |
| Net Income (ttm) | 19.45B |
| Shares Out | 179.11M |
| EPS (ttm) | 108.58 |
| PE Ratio | 12.50 |
| Forward PE | 11.25 |
| Dividend | 5.75 (0.42%) |
| Ex-Dividend Date | Nov 27, 2024 |
| Volume | 360,790 |
| Open | 1,379.80 |
| Previous Close | 1,374.75 |
| Day's Range | 1,353.05 - 1,386.40 |
| 52-Week Range | 752.45 - 1,639.00 |
| Beta | 0.51 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 8, 2024 |
About NATCO Pharma
NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosph... [Read more]
Financial Performance
In 2023, NATCO Pharma's revenue was 40.02 billion, an increase of 47.76% compared to the previous year's 27.09 billion. Earnings were 13.88 billion, an increase of 94.09%.
Financial StatementsNews
Natco Pharma submits ANDA for Risdiplam for oral solution
Natco Pharma has announced its submission of an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification to the U.S. FDA for the generic version of EVRYSDI® (Risdiplam) 0.75 mg/mL Ora...
Natco Pharma Q2 FY24-25 Results: Revenue rises 32.1% YoY to ₹1,371 crore, profit surges 81.2% to ₹676.5 crore
Natco Pharma Limited has reported strong financial results for the second quarter ended September 30, 2024, showcasing significant growth in both revenue and profitability. Quarterly Financial Highlig...
Natco Pharma Q2 FY25 results: Stock surge over 2% ahead of result announcement
Shares of Natco Pharma saw a notable rise of over 2%, reaching an intraday high of ₹1,435.40, as investors eagerly anticipate the company’s upcoming Q2 FY25 results. The stock opened at ₹1,402.00 and ...
Q2 results today: Hyundai Motor India, Bosch, Zydus Lifesciences, Nykaa, Unno Minda, 3M India, Natco Pharma, TBO Tek among companies to announce earnings
A diverse group of companies, including Hyundai Motor India, Bosch, Zydus Lifesciences, and FSN E-Commerce Ventures (Nykaa), are set to announce their Q2 FY24-25 financial results today. Here’s a list...
Health groups join patent war over spinal muscular atrophy drug
Public health groups are challenging Roche's attempt to block a generic version of its expensive Spinal Muscular Atrophy drug, Risdiplam. They argue that Roche's patent infringement lawsuit against Na...
Pharma stocks today: Gland Pharma rises 1.53%, Aurobindo Pharma up 1.38%, while Natco Pharma falls 1.40%, and Laurus Labs down 1.41%
As of 10:31 AM, the pharma sector has witnessed both gains and losses. Gland Pharma is the top gainer, rising by 1.53% to ₹1,675.40, followed by Aurobindo Pharma, up 1.38% at ₹1,493.00. Mankind Pharma...
Pharma Stocks Update: Check out how Cipla, Lupin, Abbott India, Divi’s Lab, Zydus Life, Dr Reddy’s Lab are performing today
JB Chem rises 1.91%, Biocon gains 0.87%, while Natco Pharma drops 2.65% and Gland Pharma slips 1.38% in today's trade.
Top Morning Losers Today: Home First, RITES, ICICI Securities, Natco Pharma, Thermax lead declines [Oct 10]
Several stocks are facing downward pressure in the morning session as of 10:41 AM. Here are the top losers: Home First Finance (HOMEFIRST): The stock fell by 4.90%, trading at ₹1,245.25, down ₹64.10. ...
Pharma Stocks Update: Natco Pharma gains 2.99%, Glenmark rises 0.07%, Granules falls 3.83%
As of 2:38 PM, the Nifty Pharma index saw a mixed performance with some stocks showing notable gains while others faced losses. Natco Pharma, Glenmark, and Ajanta Pharma were the top gainers, while Gr...
NATCO Pharma shares surge 3% after announcing settlement in U.S. patent litigation
NATCO Pharma shares jumped more than 3% in morning trade after the company announced that Mylan Pharmaceuticals Inc. and Novo Nordisk had settled a U.S. patent litigation concerning developing a gener...
NATCO Pharma announces settlement in U.S. patent litigation for generic Ozempic
NATCO Pharma Limited has announced that Mylan Pharmaceuticals Inc. and Novo Nordisk have settled a U.S. patent litigation concerning the development of a generic version of Ozempic (Semaglutide). The ...
Natco Pharma stock surges over 4% after submitting FDA application for lung cancer treatment
Natco Pharma (NATCOPHARM) shares surged by 4.19%, trading at ₹1,562.00 at 9:59 AM, following the company’s announcement of submitting a product application to the U.S. Food and Drug Administration (FD...
Natco Pharma submits ANDA for generic version of Tabrecta, a $126M US market drug
Natco Pharma Limited has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for a generic version of Tabrecta (Capmatinib hydrochloride). The applicati...
Q1 2025 Natco Pharma Ltd Earnings Call Transcript
Q1 2025 Natco Pharma Ltd Earnings Call Transcript